Recombinant ADAMTS13 Shows Superior Efficacy Over Plasma in Congenital TTP: A Paradigm Shift in Replacement Therapy – Blood Journals Portfolio
A recent study published by Blood Journals Portfolio (May 2024) available here demonstrates that recombinant ADAMTS13 (rADAMTS13) offers significantly more efficient ADAMTS13 replacement than traditional plasma infusions in patients with congenital thrombotic thrombocytopenic purpura (cTTP).
This finding marks a critical step forward in targeted therapy for patients with severe ADAMTS13 deficiency, a condition that leads to life-threatening microangiopathic hemolytic anemia and thrombocytopenia. Unlike plasma, which delivers ADAMTS13 in variable and limited concentrations, recombinant formulations offer predictable pharmacokinetics, higher bioavailability, and eliminate the risks associated with plasma-derived products, including allergic reactions and pathogen transmission.
These results underscore the potential of rADAMTS13 to become the standard of care in managing cTTP, improving prophylactic and acute-phase treatment outcomes.
Blood Journals Portfolio shared on X:
“Recombinant ADAMTS13 can supply ADAMTS13 more efficiently than plasma to patients with congenital thrombotic thrombocytopenic purpura.”
Title: Therapeutic switch from plasma to recombinant ADAMTS13 for patients with congenital TTP from Japanese real-world data
Autors: Kazuya Sakai, Atsushi Hamamura, Yoshiko Yoshimura, Miyuki Abe, Yoshiyuki Ogawa, Kazuki Tanaka, Norimichi Hattori, Tazuko Tokugawa, Rie Kanai, Fumiyoshi Ikejiri, Masahiro Takeyama, Teruhisa Taoka, Naoki Fujita, Minoru Kanaya, Katsuyoshi Koh, Hiroshi Shiragami, Hidekazu Azumi, Kenki Saito, Masanori Matsumoto
See more in-depth professional insights at Hemostasis Today, where we bring you the latest advances in thrombosis, hemostasis, and rare bleeding disorders.
-
Sep 29, 2025, 12:54Microfluidic Technology Uncovers Ongoing TTP Disease Activity
-
Sep 29, 2025, 12:43Advancing Thrombosis Research: MRI-Based Methodology for Studying Thrombus Resolution
-
Sep 29, 2025, 05:58Samwel Mikaye on Understanding, Diagnosing, and Managing Deep Venous Thrombosis (DVT)
-
Sep 28, 2025, 14:08Mary Cushman: Dr Warkentin Is a Giant in Hematology
-
Sep 28, 2025, 13:31Michael Makris Highlights Vaccine Misinformation and Its Risks
-
Sep 29, 2025, 12:33Allison Wheeler: Some Days I Love Science a Little Bit More
-
Sep 29, 2025, 06:23Yudi Hardianto and Colleagues Give a Review on Stroke Rehabilitation in LMICs
-
Sep 29, 2025, 04:42Wolfgang Miesbach on the Bi8 Study: A Novel FVIII-Mimetic Antibody Gene Therapy for Haemophilia A
-
Sep 29, 2025, 04:16Salvador Payán Pernía on Equity Challenges in Access to Gene Therapy for Hemoglobinopathies
-
Sep 29, 2025, 04:02Nicolas Gendron: A Very Nice Demonstration by The Authors - Coffee is Associated with Reduced Risk of VTE
-
Sep 29, 2025, 05:06Sue Bacon on the Importance of Addressing Hospital-Acquired DVT and PE
-
Sep 24, 2025, 11:06Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039
-
Sep 23, 2025, 06:40Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
-
Sep 22, 2025, 07:10Aspirin Beyond the Heart․ Targeting PI3K-Altered Colorectal Cancer
-
Sep 22, 2025, 06:04ClearPlasma: A New Filter Technology to Enhance Clot Stability in Donated Plasma
-
Sep 29, 2025, 07:02Kambua Manundu: We Walked to Protest the Countless Lives of Women We Have Lost to Post Partum Hemorrhage
-
Sep 29, 2025, 06:41Ouma Oluga Unveiled Plans to Make Sickle Cell Screening Mandatory in Kenya at 80th UN General Assembly
-
Sep 29, 2025, 04:51Nathan Connell on Breakthrough Gene Therapy Advancing Care for People with Hemophilia
-
Sep 29, 2025, 04:28Emmeran Hauser: Fantastic to See First Results of Our Work in Europe
-
Sep 28, 2025, 10:33Côme Bommier: Burnout Is Common Among Hematology Professionals